| Literature DB >> 15261560 |
Carlo Pozzilli1, Fabiana Marinelli, Silvia Romano, Francesca Bagnato.
Abstract
Corticosteroids (Cs) are widely used for treatment of multiple sclerosis (MS) acute relapses because of the potent immunosuppressive and anti-inflammatory properties. As for patients with relapsing-remitting (RR) MS, short-term administrations of Cs markedly less severity of symptoms and promote faster recovery of clinical attacks. Chronic administrations of Cs significantly diminish the formation of T1 hypointense lesions and the progression of brain atrophy. As for patients with secondary progressive MS treatment with Cs delays the time to onset of sustained disability. Finally the association between methylprednisolone and interferon beta (IFNbeta) leads the recovery of active lesions at greater extent and reduces the formation of neutralizing antibodies (NABs) against IFNbeta in patients with RRMS. Copyright 2004 Elsevier B.V.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15261560 DOI: 10.1016/j.jns.2004.04.019
Source DB: PubMed Journal: J Neurol Sci ISSN: 0022-510X Impact factor: 3.181